Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoma × fludarabine × Clear all

Phase

Phase 2 37 Phase 1 35 Phase 1/2 19 Phase 3 3 Phase EARLY_PHASE1 2 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Mantle-Cell 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Older Patients 1 Myasthenia Gravis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, B-Cell 1 Autoimmune Diseases 1

Interventions

Cyclophosphamide 9 Etoposide 6 Doxorubicin 5 Cytarabine 5 Prednisone 4 Vincristine 3 Trimethoprim, Sulfamethoxazole Drug Combination 3 Rituximab 3 Methotrexate 3 Filgrastim 3 gamma-Globulins 2 etoposide phosphate 2 Triptorelin Pamoate 2 Radiotherapy 2 Melphalan 2 Immunoglobulins, Intravenous 2 Cyclosporine 2 Ciprofloxacin 2 vedolizumab 1 ruxolitinib 1 rasburicase 1 prednisolone phosphate 1 pegfilgrastim 1 pegaspargase 1 nelarabine 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 fludarabine phosphate 1 fludarabine 1 epratuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00641095 2018-10-31

MCLPIII

University College, London

Phase 2/3 Completed

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡